Clinical and Molecular Evolution of an ALK-Driven Infant-Type Hemispheric Glioma Treated Sequentially With Second- and Third-Generation Anaplastic Lymphoma Kinase Inhibitors
Por:
Gene-Olaciregui N, Pérez-Somarriba M, Santa-María López V, Cruz-Martínez O, Gomez-Gonzalez S, Castañeda-Heredia A, Suñol M, Rovira-Zurriaga C, Muchart-Lopez J, Hinojosa J, Morales-La Madrid A and Lavarino C
Publicada:
1 ene 2023
Resumen:
Filiaciones:
Gene-Olaciregui N:
Laboratory of Molecular Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Pérez-Somarriba M:
Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Santa-María López V:
Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Cruz-Martínez O:
Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Gomez-Gonzalez S:
Laboratory of Developmental Tumor Biology, Institut de Recerca Sant Joan de Déu, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Castañeda-Heredia A:
Pediatric Solid Tumor Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Suñol M:
Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain
Rovira-Zurriaga C:
Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain
Muchart-Lopez J:
Department of Radiology, Hospital Sant Joan de Déu, Barcelona, Spain
Hinojosa J:
Department of Neurosurgery, Hospital Sant Joan de Déu, Barcelona, Spain
Morales-La Madrid A:
Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Lavarino C:
Laboratory of Molecular Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
hybrid
|